|
|
 |
|
Viewing report
|
|
|
|
Commercializing Peptides in Cancer: The Faster Route to Consider Your Options and Position of Others
Bioseeker, Nov 2011, Pages: 906
This report will excel your competitive awareness and decrease your decision making time in managing peptide drug development in cancer. Find out whether you are number one, two or further down the ladder in this highly competitive market. Locate the right drugs to benchmark against and see were others may have succeeded or failed before you.
This report comprises defined and up to date development strategies for 152 peptide drugs in oncology within the portfolio of 104 companies world-wide, from Ceased to Marketed. The report extensively analyses their 123 identified drug targets, organized into 103 drug target strategies, and assesses them in 56 cancer indications. BioSeeker has applied its unique drug assessment methodology to stratify the peptide drug pipeline in oncology and discern the level of competition in fine detail.
Major Findings from this report:
- The identified competitive landscape of peptide drugs in cancer is split between the 53% which have unique drug target strategies and the other part (47%) which have head-to-head target competing peptide drugs in 22 different clusters. The latter has a competing ratio which is two times higher than the comparable average of the peptide drugs in general. Contributing to this fact is heavily utilized drug target strategies like: GNRHR and MUC1.
- Eight out of ten drug target strategies in Phase III development are new to peptide drugs in cancer and the greatest numbers of new target strategies are found in Preclinical (32%) and Phase II development (15%).
- The highest number of described target strategies among peptide drugs are found in Breast Cancer, Prostate Cancer and Pancreatic Cancer. Peptide drugs are experiencing targeting competition in only two out of every ten cancer indications described, and more so in Prostate Cancer.
- The highest number of described drug target strategies (total) of peptide drugs belongs to Cancer Research Technology (7), Affymax (4), Esperance Pharmaceuticals (3) and Raptor Pharmaceutical (3).
- From an indication perspective it is Abbott (15), Esperance Pharmaceuticals (9) and AngioChem (8) which take the lead in the widest coverage of cancer indications.
The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies’ pipeline and portfolio planning (PPP) in cancer by:
- Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives
- Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug's properties
- Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities
- Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities
- Supporting development of integrative molecule, pathway and disease area strategies
- Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment
This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for any peptide drug in cancer to ensure that the optimal market conditions exist by the time the product is commercialized.
|
|
|
|
